Exploring the structural aspects of ureido-amino acid-based APN inhibitors: a validated comparative multi-QSAR modelling study

References

• S.A. Amin, N. Adhikari, and T. Jha, Design of aminopeptidase N inhibitors as anti-cancer agents, J. Med. Chem. 61 (2018), pp. 6468–6490. doi:10.1021/acs.jmedchem.7b00782.
   PubMed Web of Science ®Google Scholar
• P. Mina-Osorio, The moonlighting enzyme CD13: Old and new functions to target, Trends Mol. Med. 14 (2008), pp. 361–371. doi:10.1016/j.molmed.2008.06.003.
   PubMed Web of Science ®Google Scholar
• D. Reinhold, A. Biton, S. Pieper, U. Lendeckel, J. Faust, K. Neubert, U. Bank, M. Täger, S. Ansorge, and S. Brocke, Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation, Int. Immunopharmacol. 6 (2006), pp. 1935–1942. doi:10.1016/j.intimp.2006.07.023.
   PubMed Web of Science ®Google Scholar
• L. Chen, Y.L. Lin, G. Peng, and F. Li, Structural basis for multifunctional roles of mammalian aminopeptidase N, Proc. Natl. Acad. Sci. USA 109 (2012), pp. 17966–17971. doi:10.1073/pnas.1210123109.
   PubMed Web of Science ®Google Scholar
• N.M. Hooper, Families of zinc metalloproteases, FEBS Lett. 354 (1994), pp. 1–6. doi:10.1016/0014-5793(94)01079-X.
   PubMed Web of Science ®Google Scholar
• A.N. Santos, J. Langner, M. Herrmann, and D. Riemann, Aminopeptidase N/CD13 is directly linked to signal transduction pathways in monocytes, Cell. Immunol. 201 (2000), pp. 22−32. doi:10.1006/cimm.2000.1629.
   PubMed Web of Science ®Google Scholar
• S.L. Larsen, L.O. Pedersen, S. Buus, and A. Stryhn, T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides, J. Exp. Med. 184 (1996), pp. 183–189. doi:10.1084/jem.184.1.183.
   PubMed Web of Science ®Google Scholar
• I. Saiki, J. Yoneda, I. Azuma, H. Fujii, F. Abe, M. Nakajima, and T. Tsuruo, Role of aminopeptidase N (CD13) in tumor‐cell invasion and extracellular matrix degradation, Int. J. Cancer 54 (1993), pp. 137–143. doi:10.1002/()1097-0215.
   PubMed Web of Science ®Google Scholar
• C. Liu, Y. Yang, L. Chen, Y.-L. Lin, and L. Fang, A unified mechanism for aminopeptidase N-based tumor cell motility and tumor-homing therapy, J. Biol. Chem. 289 (2014), pp. 34520–34529. doi:10.1074/jbc.M114.566802.
   PubMed Web of Science ®Google Scholar
• D.E. Wentworth and K.V. Holmes, Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): Influence of N-linked glycosylation, J. Virol. 75 (2001), pp. 9741–9752. doi:10.1128/JVI.75.20.9741-9752.2001.
   PubMed Web of Science ®Google Scholar
• A.F. Kolb, A. Hegyi, J. Maile, A. Heister, M. Hagemann, and S.G. Siddell, Molecular analysis of the coronavirus-receptor function of aminopeptidase N, Adv. Exp. Med. Biol. 440 (1998), pp. 61–67.
   PubMed Web of Science ®Google Scholar
• S.M. Tusell, S.A. Schittone, and K.V. Holmes, Mutational analysis of aminopeptidase N, a receptor for several group 1 coronaviruses, identifies key determinants of viral host range, J. Virol. 81 (2007), pp. 1261–1273. doi:10.1128/JVI.01510-06.
   PubMed Web of Science ®Google Scholar
• M. Wickström, R. Larsson, P. Nygren, and J. Gullbo, Aminopeptidase N (CD13) as a target for cancer chemotherapy, Cancer Sci. 102 (2011), pp. 501−508. doi:10.1111/j.1349-7006.2010.01826.x.
   PubMed Web of Science ®Google Scholar
• J.M. Martínez, I. Prieto, M.J. Ramírez, C. Cueva, F. Alba, and M. Ramírez, Aminopeptidase activities in breast cancer tissue, Clin. Chem. 45 (1999), pp. 1797–1802.
   PubMed Web of Science ®Google Scholar
• G. Severini, L. Gentilini, and C. Tirelli, Diagnostic evaluation of alanine aminopeptidase as serum marker for detecting cancer, Cancer Biochem. Biophys. 12 (1991), pp. 199–204.
   PubMedGoogle Scholar
• P. Surowiak, M. Drąg, V. Materna, S. Suchocki, R. Grzywa, M. Spaczyński, M. Dietel, J. Oleksyszyn, M. Zabel, and H. Lage, Expression of aminopeptidase N/CD13 in human ovarian cancers, Int. J. Gynecol. Cancer 16 (2006), pp. 1783–1788. doi:10.1111/j.1525-1438.2006.00657.x.
   PubMed Web of Science ®Google Scholar
• M. Terauchi, H. Kajiyama, K. Shibata, K. Ino, A. Nawa, S. Mizutani, and F. Kikkawa, Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells, BMC Cancer 7 (2007), pp. 140. doi:10.1186/1471-2407-7-140.
   PubMed Web of Science ®Google Scholar
• H. Tsukamoto, K. Shibata, H. Kajiyama, M. Terauchi, A. Nawa, and F. Kikkawa, Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer, BMC Cancer. 8 (2008), pp. 74. doi:10.1186/1471-2407-8-74.
   PubMed Web of Science ®Google Scholar
• X. Wang, Z. Niu, Y. Jia, M. Cui, L. Han, Y. Zhang, Z. Liu, D. Bi, and S. Liu, Ubenimex inhibits cell proliferation, migration and invasion by inhibiting the expression of APN and inducing autophagic cell death in prostate cancer cells, Oncol. Rep. 35 (2016), pp. 2121–2130. doi:10.3892/or.2016.4611.
   PubMed Web of Science ®Google Scholar
• N. Haraguchi, H. Ishii, K. Mimori, F. Tanaka, M. Ohkuma, H.M. Kim, H. Akita, D. Takiuchi, H. Hatano, H. Nagano, and G.F. Barnard, CD13 is a therapeutic target in human liver cancer stem cells, J. Clin. Invest. 120 (2010), pp. 3326–3339. doi:10.1172/JCI42550.
   PubMed Web of Science ®Google Scholar
• H. Hashida, A. Takabayashi, M. Kanai, M. Adachi, K. Kondo, N. Kohno, Y. Yamaoka, and M. Miyake, Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer, Gastroenterology 122 (2002), pp. 376–386. doi:10.1053/gast.2002.31095.
   PubMed Web of Science ®Google Scholar
• N. Ikeda, Y. Nakajima, T. Tokuhara, N. Hattori, M. Sho, H. Kanehiro, and M. Miyake, Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma, Clin. Cancer Res. 9 (2003), pp. 1503–1508.
   PubMed Web of Science ®Google Scholar
• A. Kido, S. Krueger, C. Haeckel, and A. Roessner, Possible contribution of aminopeptidase N (APN/CD13) to invasive potential enhanced by interleukin-6 and soluble interleukin-6 receptor in human osteosarcoma cell lines, Clin. Exp. Metastasis 17 (1999), pp. 857–863. doi:10.1023/A:1006794617406.
   PubMed Web of Science ®Google Scholar
• L. Pang, N. Zhang, Y. Xia, D. Wang, G. Wang, and X. Meng, Serum APN/CD13 as a novel diagnostic and prognostic biomarker of pancreatic cancer, Oncotarget 7 (2016), pp. 77854–77864. doi:10.18632/oncotarget.v7i47.
   PubMedGoogle Scholar
• Y. Inagaki, W. Tang, L. Zhang, G. Du, W. Xu, and N. Kokudo, Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis, Biosci. Trends 4 (2010), pp. 56–60.
   PubMed Web of Science ®Google Scholar
• L. Guzman-Rojas, R. Rangel, A. Salameh, J.K. Edwards, E. Dondossola, Y.G. Kim, A. Saghatelian, R.J. Giordano, M.G. Kolonin, F.I. Staquicini, and E. Koivunen, Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment, Proc. Natl. Acad. Sci. USA 109 (2012), pp. 1637–1642. doi:10.1073/pnas.1120790109.
   PubMed Web of Science ®Google Scholar
• H. Umezawa, T. Aoyagi, H. Suda, M. Hamada, and T. Takeuchi, Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes, J. Antibiot. 29 (1976), pp. 97–99. doi:10.7164/antibiotics.29.97.
   PubMed Web of Science ®Google Scholar
• D.H. Rich, B.J. Moon, and S. Harbeson, Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes, J. Med. Chem. 27 (1984), pp. 417–422. doi:10.1021/jm00370a001.
   PubMed Web of Science ®Google Scholar
• B.R. Lampret, J. Kidri, B. Kralj, L. Vitale, M. Pokorny, and M. Renko, Lapstatin, a new aminopeptidase inhibitor produced by Streptomyces rimosus, inhibits autogenous aminopeptidases, Arch. Microbiol. 171 (1999), pp. 397–404. doi:10.1007/s002030050726.
   PubMed Web of Science ®Google Scholar
• M. Nagai, F. Kojima, H. Naganawa, M. Hamada, T. Aoyagi, and T. Takeuchi, Phebestin, a new inhibitor of aminopeptidase N, produced by Streptomyces sp. MJ716-m3, J. Antibiot. 50 (1997), pp. 82–84. doi:10.7164/antibiotics.50.82.
   PubMed Web of Science ®Google Scholar
• L. Su, Y. Jia, L. Zhang, Y. Xu, H. Fang, and W. Xu, Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors, Bioorg. Med. Chem. 19 (2012), pp. 900–906. doi:10.1016/j.bmc.2010.11.066.
   Google Scholar
• L. Su, Y. Jia, L. Zhang, Y. Xu, H. Fang, and W. Xu, Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors, Bioorg. Med. Chem. 20 (2012), pp. 3807–3815. doi:10.1016/j.bmc.2012.04.035.
   PubMedGoogle Scholar
• L. Su, J. Cao, Y. Jia, X. Zhang, H. Fang, and W. Xu, Development of synthetic aminopeptidase N/CD13 inhibitors to overcome cancer metastasis and angiogenesis, ACS Med. Chem. Lett. 3 (2012), pp. 959–964. doi:10.1021/ml3000758.
   PubMed Web of Science ®Google Scholar
• C. Ma, K. Jin, J. Cao, L. Zhang, X. Li, and W. Xu, Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN), Bioorg. Med. Chem. 21 (2013), pp. 1621–1627. doi:10.1016/j.bmc.2013.01.068.
   PubMedGoogle Scholar
• C. Ma, J. Cao, X. Liang, Y. Huang, P. Wu, Y. Li, W. Xu, and Y. Zhang, Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation, Eur. J. Med. Chem. 108 (2016), pp. 21–27. doi:10.1016/j.ejmech.2015.11.021.
   PubMed Web of Science ®Google Scholar
• J. Devillers, A. Larghi, and C. Lagneau, QSAR modelling of synergists to increase the efficacy of deltamethrin against pyrethroid-resistant Aedes aegypti mosquitoes, SAR QSAR Environ. Res. 29 (2018), pp. 613–629. doi:10.1080/1062936X.2018.1503846.
   PubMed Web of Science ®Google Scholar
• J.P. Doucet, E. Papa, A. Doucet-Panaye, and J. Devillers, QSAR models for predicting the toxicity of piperidine derivatives against Aedes aegypti, SAR QSAR Environ. Res. 28 (2017), pp. 451–470. doi:10.1080/1062936X.2017.1328855.
   PubMed Web of Science ®Google Scholar
• D. López-Malo, J.I. Bueso-Bordils, M.J. Duart, P.A. Alemán-López, R.V. Martín-Algarra, G.M. Antón-Fos, L. Lahuerta-Zamora, and J. Martínez-Calatayud, QSPR studies on the photoinduced-fluorescence behaviour of pharmaceuticals and pesticides, SAR QSAR Environ. Res. 28 (2017), pp. 609–620. doi:10.1080/1062936X.2017.1358212.
   PubMed Web of Science ®Google Scholar
• ChemDraw Ultra 5.0. Cambridge Soft Corporation, USA, 2010; software available at http://www.cambridgesoft.com.
   Google Scholar
• DRAGON 6.0. TALETE SRL: Italy, 2001; Available at http://www.talete.mi.it/products/dragon_description.htm.
   Google Scholar
• S. Banerjee, N. Adhikari, S.A. Amin, and T. Jha, Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study, J. Biomol. Struct. Dyn. (2019), pp. 1–14. (In press). doi:10.1080/07391102.2019.1617782.
   Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, S. Bhargava, T. Jha, and S. Gayen, Structural exploration of hydroxyethylamines as HIV-1 protease inhibitors: New features identified, SAR QSAR Environ. Res. 29 (2018), pp. 385–408. doi:10.1080/1062936X.2018.1447511.
   PubMed Web of Science ®Google Scholar
• S. Sanyal, S.A. Amin, N. Adhikari, and T. Jha, QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors, SAR QSAR Environ. Res. 30 (2019), pp. 247–263. doi:10.1080/1062936X.2019.1588159.
   PubMed Web of Science ®Google Scholar
• M. Hall, E. Frank, G. Holmes, B. Pfahringer, P. Reutemann, and I.H. Witten, The WEKA data mining software: An update, SIGKDD Explor. 11 (2009), pp. 10–18. doi:10.1145/1656274.1656278.
   Google Scholar
• S.K. Baidya, S.A. Amin, S. Banerjee, N. Adhikari, and T. Jha, Structural exploration of arylsulfonamide-based ADAM17 inhibitors through validated comparative multi-QSAR modelling studies, J. Mol. Struct. 1185 (2019), pp. 128–142. doi:10.1016/j.molstruc.2019.02.081.
   Web of Science ®Google Scholar
• QSAR tools. DTC laboratory, India, 2020; software available at https://dtclab.webs.com/software-tools.
   Google Scholar
• S.A. Amin, N. Adhikari, S. Bhargava, S. Gayen, and T. Jha, An integrated QSAR modeling approach to explore the structure–property and selectivity relationships of N-benzoyl-L-biphenylalanines as integrin antagonists, Mol. Divers. 22 (2018), pp. 129–158. doi:10.1007/s11030-017-9789-9.
   PubMed Web of Science ®Google Scholar
• K. Roy, S. Kar, and R.N. Das, Understanding the Basics of QSAR for Applications in Pharmaceutical Sciences and Risk Assessment, Academic Press, London, 2015.
   Google Scholar
• S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, First report on the structural exploration and prediction of new BPTES analogs as glutaminase inhibitors, J. Mol. Struct. 1143 (2017), pp. 49–64. doi:10.1016/j.molstruc.2017.04.020.
   Web of Science ®Google Scholar
• STATISTICA Version 7. Statistical Software of StatSoft, Inc., Tulsa, USA; software available at http://www.statsoft.com.
   Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Exploring in house glutamate inhibitors of matrix metalloproteinase-2 through validated robust chemico-biological quantitative approaches, Struct. Chem. 29 (2018), pp. 285–297. doi:10.1007/s11224-017-1028-6.
   Web of Science ®Google Scholar
• E. Goya-Jorge, T.Q. Doan, M.L. Scippo, M. Muller, R.M. Giner, S.J. Barigye, and R. Gozalbes, Elucidating the aryl hydrocarbon receptor antagonism from a chemical-structural perspective, SAR QSAR Environ. Res. 31 (2020), pp. 209–226. doi:10.1080/1062936X.2019.1708460.
   PubMed Web of Science ®Google Scholar
• J.A. Castillo-Garit, G.M. Casañola-Martin, S.J. Barigye, H. Pham-The, F. Torrens, and A. Torreblanca, Machine learning-based models to predict modes of toxic action of phenols to Tetrahymena pyriformis, SAR QSAR Environ. Res. 28 (2017), pp. 735–747. doi:10.1080/1062936X.2017.1376705.
   PubMed Web of Science ®Google Scholar
• J.O. Berger, Statistical Decision Theory and Bayesian Analysis, Springer Science & Business Media, USA, 2013.
   Google Scholar
• G.E.P. Box and G.C. Tiao, Bayesian Inference in Statistical Analysis, John Wiley & Sons, USA, 2011.
   Google Scholar
• T. Jha, N. Adhikari, A. Saha, and S.A. Amin, Multiple molecular modelling studies on some derivatives and analogues of glutamic acid as matrix metalloproteinase-2 inhibitors, SAR QSAR Environ. Res. 29 (2018), pp. 43–68. doi:10.1080/1062936X.2017.1406986.
   PubMed Web of Science ®Google Scholar
• B. Bhardwaj, A.T.K. Baidya, S.A. Amin, N. Adhikari, T. Jha, and S. Gayen, Insight into structural features of phenyltetrazole derivatives as ABCG2 inhibitors for the treatment of multidrug resistance in cancer, SAR QSAR Environ. Res. 30 (2019), pp. 457–475. doi:10.1080/1062936X.2019.1615545.
   PubMed Web of Science ®Google Scholar
• Discovery Studio 3.0 (DS 3.0). Accelrys Inc., CA, USA, 2015; software available at http://www.accelrys.com.
   Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2!, J. Mol. Graph. Model 20 (2002), pp. 269–276. doi:10.1016/S1093-3263(01)00123-1.
   PubMed Web of Science ®Google Scholar
• Q. Wang, M. Chen, H. Zhu, J. Zhang, H. Fang, B. Wang, and W. Xu, Design, synthesis, and QSAR studies of novel lysine derives as amino-peptidase N/CD13 inhibitors, Bioorg. Med. Chem. 16 (2008), pp. 5473–5481. doi:10.1016/j.bmc.2008.04.012.
   PubMedGoogle Scholar
• X. Wang, F. Jing, H. Zhu, H. Fang, J. Zhang, and W. Xu, Activity screening and structure-activity relationship of the hit compounds targeting APN/CD13, Fundam. Clin. Pharmacol. 25 (2011), pp. 217–228. doi:10.1111/j.1472-8206.2010.00844.x.
   PubMed Web of Science ®Google Scholar
• Y. Xu, L. Zhang, M. Li, W. Xu, H. Fang, and L. Shang, QSAR studies of aminopeptidase N/CD13 (APN) inhibitors with the scaffold 3-phenylpropane-1,2-diamine and molecular docking, Med. Chem. Res. 21 (2012), pp. 1000–1015. doi:10.1007/s00044-011-9597-1.
   Web of Science ®Google Scholar
• A.K. Halder, A. Saha, and T. Jha, Exploration of structural and physicochemical requirements and search of virtual hits for aminopeptidase N inhibitors, Mol. Divers. 17 (2013), pp. 123–137. doi:10.1007/s11030-013-9422-5.
   PubMed Web of Science ®Google Scholar
• X. Tang, Q. Qu, B. Kuang, S. Li, and G. Tu, 3D-QSAR studies on flavone-8-acetic acid derivatives of aminopeptidase N inhibitors, Med. Chem. 11 (2015), pp. 764–770. doi:10.2174/1573406411666150714111256.
   PubMed Web of Science ®Google Scholar
• Q. Qu, X. Tang, B. Kuang, S. Li, and G. Tu, 3D-QSAR studies, molecular dynamics simulation and free energy calculation of APN inhibitors, Int. J. Pharmacol. 11 (2015), pp. 920–928. doi:10.3923/ijp.2015.920.928.
   Google Scholar
• O. Farsa and M. Haluska, A single-and multiparametric QSAR study of aminopeptidase N inhibitors, FARMACIA 64 (2016), pp. 283–290.
   Web of Science ®Google Scholar
• J. Ziemska, J. Solecka, and M. Jaron´czyk, QSAR, docking studies and toxicology prediction of isoquinoline derivatives as leucine aminopeptidase inhibitors, Chem. Pap. 71 (2017), pp. 2557–2568. doi:10.1007/s11696-017-0251-3.
   Web of Science ®Google Scholar
• N. Faraji, T. Zebardast, A. Zarghi, and Z. Hajimahdi, QSAR modeling of aminopeptidase N/CD13 (APN) inhibitory activity of some leucine ureido derivatives by GA-MLR and SW-MLR methods, Lett. Drug. Des. Discov. 14 (2017), pp. 1348–1357. doi:10.2174/1570180814666170529084557.
   Web of Science ®Google Scholar
• O. Farsa, J. Kana, I. Macko, J. Zelazkova, J. Podlipna, A. Cirkva, J. Maxa, and K. Stastnv, Synthesis and aminopeptidase N inhibiting activity of 3-(nitrophenoxymethyl)-[1,3,2]dioxaborolan-2-ols and their open analogues, Acta Pol. Pharm. 74 (2017), pp. 127–135.
   PubMed Web of Science ®Google Scholar